Cited 0 times in
Pituitary Diseases and COVID-19 Outcomes in South Korea: A Nationwide Cohort Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김경민 | - |
dc.date.accessioned | 2023-08-23T00:19:13Z | - |
dc.date.available | 2023-08-23T00:19:13Z | - |
dc.date.issued | 2023-07 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/196214 | - |
dc.description.abstract | The pituitary gland is either directly or indirectly impacted by SARS-CoV-2 infection. As a consequence of SARS-CoV-2 infection, hypothalamic–pituitary dysfunction or pituitary apoplexy can occur. This study aimed to investigate severe COVID-19 outcomes and COVID-19-related mortality in patients with underlying pituitary disease in Korea using a nationwide cohort database. The data required for this study were obtained from the Health Insurance Review and Assessment Service of Korea. Patients with SARS-CoV-2 infection between January 2020 and December 2021 were divided into the following three groups and analyzed: Group A, those who were hospitalized for SARS-CoV-2 infection without underlying pituitary disease (n = 725,170); Group B, those who were hospitalized for SARS-CoV-2 infection with underlying pituitary disease without exposure to systemic steroids (n = 1509); and Group C, patients with underlying pituitary disease and exposure to systemic steroids (n = 365). Differences in severe COVID-19, requirement for oxygen therapy, intensive care unit admission, application of invasive ventilation or use of extracorporeal membrane oxygenation, and COVID-19-related deaths between groups were then analyzed. Group C had the highest rates of hospitalization after COVID-19 infection (82.2%) and mortality within 30 days of infection (6.8%). Group B had a 1.3-fold increase in severe COVID-19 outcomes compared to Group A. Group C had 1.8-fold and 1.3-fold increases in severe COVID-19 outcomes compared to Group A and Group B, respectively. Group C also had 2.34 and 3.24 times higher mortality rates within 30 days of COVID-19 infection than Group A and Group B, respectively. In conclusion, patients with pituitary disease who are receiving systemic steroids have poorer outcomes and higher mortality associated with COVID-19. Therefore, thorough COVID-19 infection control is required in these patients. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | MDPI AG | - |
dc.relation.isPartOf | JOURNAL OF CLINICAL MEDICINE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Pituitary Diseases and COVID-19 Outcomes in South Korea: A Nationwide Cohort Study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Jeonghoon Ha | - |
dc.contributor.googleauthor | Kyoung Min Kim | - |
dc.contributor.googleauthor | Dong-Jun Lim | - |
dc.contributor.googleauthor | Keeho Song | - |
dc.contributor.googleauthor | Gi Hyeon Seo | - |
dc.identifier.doi | 10.3390/jcm12144799 | - |
dc.contributor.localId | A00295 | - |
dc.relation.journalcode | J03556 | - |
dc.identifier.eissn | 2077-0383 | - |
dc.identifier.pmid | 37510914 | - |
dc.subject.keyword | COVID-19 | - |
dc.subject.keyword | mortality | - |
dc.subject.keyword | pituitary disease | - |
dc.contributor.alternativeName | Kim, Kyung Min | - |
dc.contributor.affiliatedAuthor | 김경민 | - |
dc.citation.volume | 12 | - |
dc.citation.number | 14 | - |
dc.citation.startPage | 4799 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL MEDICINE, Vol.12(14) : 4799, 2023-07 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.